Online citations, reference lists, and bibliographies.
← Back to Search

Role Of Metabolic Imaging In Mesothelioma

Fabrizia Gelardi, Andrea Marciano, P. Erba, A. Chiti
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Early diagnosis and clinical staging in patients affected by malignant pleural mesothelioma (MPM) is necessary to manage individual therapy strategies. Computed tomography (CT) and magnetic resonance imaging (MRI) are routinely used for non-invasive clinical staging. Because of the complex growth pattern of MPM, it is difficult to make a clinical judgement only with morphological imaging, so 18F-FDG PET-CT represent an important adjunctive imaging tool in these patients. 18F-FDG PET-CT can be useful in detecting malignant pleural mesothelioma in patients exposed to asbestos and distinguish asbestos-related benign lesions. Combined PET-CT is essential for selecting patients with resectable disease, increasing the detection of locally advanced tumour and improve the accuracy of preoperative staging. 18F-FDG PET-CT could be useful also in risk stratification, to avoid radical surgery in cases characterized by the worst prognosis. PET-CT is gradually becoming essential in assessment of tumour response in patients undergoing chemotherapy. Metabolic imaging analysis permits the early identification of non-responders to chemotherapy, avoiding unsuccessful treatment, characterized by important toxicities and high mortality risk.
This paper references
10.1053/j.sult.2010.10.001
Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy.
P. Kinahan (2010)
10.4137/CMO.S504
Integrated 18FDG PET/CT: Utility and Applications in Clinical Oncology
I. Pinilla (2008)
10.1016/J.CTRV.2007.07.012
Assessment of tumor response in malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1148/RG.241035058
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Z. Wang (2004)
10.1371/journal.pone.0161764
The Role of 18F-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion
Yajuan Sun (2016)
10.1002/cam4.1182
Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy
P. Zucali (2017)
10.1016/S0022-5223(03)00207-1
Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma.
R. Flores (2003)
Use of PET for monitoring cancer therapy and for predicting outcome.
W. Weber (2005)
10.1007/s00259-014-2960-y
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma
E. Lopci (2014)
10.3892/ETM.2012.572
Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma.
T. Terada (2012)
10.1007/s11307-009-0203-6
Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
10.1245/s10434-010-1107-z
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)
10.1007/s00259-014-2961-x
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
R. Boellaard (2014)
10.2214/AJR.182.4.1820983
False-positive FDG positron emission tomography uptake in nonmalignant chest abnormalities.
Syed K. Asad (2004)
10.1016/j.ejrad.2016.11.009
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Shingo Kanemura (2017)
10.1148/RADIOL.2422051113
PET/CT: form and function.
T. Blodgett (2007)
10.1097/RCT.0000000000000174
Use of Computed Tomography and Positron Emission Tomography/Computed Tomography for Staging of Local Extent in Patients With Malignant Pleural Mesothelioma
T. Frauenfelder (2015)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.2214/AJR.159.5.1414807
Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability.
E. Patz (1992)
10.1016/J.CRAD.2005.05.015
Use of imaging in the management of malignant pleural mesothelioma.
R. Benamore (2005)
10.1016/j.ejrad.2016.11.019
Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma.
K. Kitajima (2017)
10.1067/MTC.2000.106529
Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
D. Schneider (2000)



Semantic Scholar Logo Some data provided by SemanticScholar